Skip to main content
Premium Trial:

Request an Annual Quote

'Not Necessarily Benign'

Premium

Prostate cancer screenings for healthy men have always been a little controversial as it's still not clear if catching the disease early is worth the risks the screen presents, says Katherine Hobson at the Wall Street Journal's Health blog. A recent report from Bloomberg News probably won't help — according to the report, needle biopsies that follow an abnormally high PSA count from a screening are resulting more and more in severe E. coli infections. Bloomberg News goes on to say that the risk of post-biopsy infection has more than doubled in less than 10 years, with some men developing sepsis. These findings show that the screening and the tests that follow are "not necessarily benign," Hobson says, and that physicians are starting to more carefully consider the risks before ordering the test.

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.